CoChat

Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations

Opie, Lionel H. · 1988 · Cardiovascular Drugs and Therapy

The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.

Abstract

With the correct selection of drug and patient, the calcium antagonists as a group can be remarkably effective at relatively low cost of serious side effects. Almost all side effects are dose related. Minor side effects include those caused by vasodilation (flushing and headaches), constipation (verapamil), and ankle edema. Serious side effects are rare and result from improper use of these agents, as when intravenous verapamil (or diltiazem) is given to patients with sinus or atrioventricular nodal depression from drugs or disease, or nifedipine to patients with aortic stenosis. The potential of a marked negative inotropic effect is usually offset by afterload reduction, especially in the case of nifedipine which actually has the most marked negative inotropic effect. Yet caution is required when even calcium antagonists, especially verapamil, are given to patients with myocardial failure unless caused by hypertensive heart disease. Drug interactions of calcium antagonists occur with other cardiovascular agents such as alpha-adrenergic blockers, beta-adrenergic blockers, digoxin, quinidine, and disopyramide. The most marked interaction with digoxin is that with verapamil, which may raise digoxin levels by over 50%. Combination therapy of calcium antagonists with beta-blockers is increasingly common, and is probably safest in the case of dihydropyridines. Other combinations being explored are those with angiotensin-converting enzyme inhibitors and diuretics.

Overview

Integrity signals

Registry

Crossref · 10.1007/bf00051233

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 99 references

Research works printed but not linked: 11

  1. Fleckenstein A. Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie LH, eds. Calcium and the Heart. London: Academic Press, 1971;135?188.
  2. Opie LH, Singh BN. Calcium channel antagonists (slow channel blockers). In: Opie LH, ed. Drugs for the Heart Second Expanded Edition. Orlando, Florida: Grune & Stratton, 1987;34?53
  3. Norris RJ, Brooks SG. Pharmacokinetics of a sustained release formulation of verapamil in young and elderly adults. In: Raftery EB, ed. Verapamil SR. Once-daily Calcium Blockade in Angina and Hypertension. Langhorne: ADIS Press International, 1987;38?46.
  4. Leisten L, Kuhlmann J, Ebner F. Side effects and pharmacodynamic interactions. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart-New York: Schattauer, 1986;270?314.
  5. Jee LD, Opie LH. Nifedipine for hypertension and angina pectoris: Interactions during combination therapy. In: Opie LH, ed. Calcium Antagonists and Cardiovascular Disease. New York: Raven Press, 1984;339?346.
  6. Bardet J, Baudet M, Rigaud M, et al. Diltiazem, a new calcium antagonist, versus propranolol in treatment of spontaneous angina pectoris (abstr). Am J Cardiol 1979; 43:416.
  7. Menasche S, Elkik F, Cocco G, et al. Synergistic antihypertensive effect of diltiazem combined with the alpha-adrenoceptor blocker alfuzosine (abstr). Ann NY Acad Sci (in press).
  8. Kleinbloesem CH, van Brummelen P, Sandberg THW, et al. Kinetic and haemodynamic interactions between nifedipine and propranolol in healthy subjects utilizing controlled rates of drug input. In: Kleinbloesem CH, ed. Nifedipine: Clinical Pharmacokinetics and Haemodynamic Effects. 's-Gravenhage: Drukkerij JH Pasmans BV, 1985;151?165.
  9. Kirch W. Dihydropyridine derivatives, influence on digoxin disposition and haemodynamics (abstr). Ann NY Acad Sci (in press).
  10. MacGregor GA: Hypertension. In: Krebs R, ed. Treatment of Cardiovascular Diseases by Adalat R (Nifedipine). Stuttgart: Schattauer, 1986; 231?258.
  11. Lahiri A, Dasgupta P, Rodrigues EA, et al. Acute drug withdrawal in patients with stable angina on long-term treatment with verapamil. In: Raftery EB, ed. Verapamil SR. Langhorne: ADIS Press International, 1987;18?29.

Cited by

Metadata

Authors
Opie, L. H.
Affiliations
University of Cape Town (ZA)
Corresponding author
Opie, Lionel H.
Venue
Cardiovascular Drugs and Therapy
Published
1988-07
Volume
2
Issue
2
Pages
177-189
ISSN
  • 0920-3206 (ISSN-L)
  • 1573-7241
OpenAlex
W1999013996
Cited by
52
References
99
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 1 · 2021: 5 · 2020: 2 · 2016: 1 · 2015: 1 · 2013: 1 · 2012: 1
FWCI
1.43
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Cardiovascular Drugs and Therapy (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
Keywords
calcium channel blockers, verapamil, diltiazem, nifedipine, adverse drug reactions, contraindications, drug interactions, beta-blocker combination therapy, dihydropyridines, negative inotropic effect, myocardial failure, aortic stenosis, alpha-blockers, ACE inhibitors, diuretics, vasodilation
MeSH terms
Calcium Channel Blockers, Cardiovascular Diseases, Drug Interactions, Drug Therapy, Combination, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.